1 41

Cited 16 times in

Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study

 Hye Jin Kang ; Won Seog Kim ; Baek-Yeol Ryoo ; Cheolwon Suh ; Jinny Park ; Jooseop Chung ; Hyeon-Seok Eom ; Hugh Chul Kim ; Sung Yong Oh ; Ho Young Kim ; Hyo Jung Kim ; Gyeong-Won Lee ; Se-Ryeon Lee ; Jin Seok Kim ; Deok-Hwan Yang ; Je-Jung Lee ; Seok Jin Kim 
 Annals of Hematology, Vol.91(4) : 543~551, 2012 
Journal Title
 Annals of Hematology 
Issue Date
We conducted a multicenter, phase II trial to investigate the efficacy and safety of rituximab plus CVP (R-CVP) combination therapy for patients with previously untreated stage III or IV marginal zone lymphoma (MZL). The treatment consisted of rituximab 375 mg/m2, cyclophosphamide 750 mg/m2 and vincristine 1.4 mg/m2 (maximum 2.0 mg) being given intravenously on day 1 and oral prednisolone 100 mg on days 1–5. The treatment was repeated every 3 weeks and this was continued for six or eight cycles. Forty-two patients were enrolled from 13 institutes in Korea. Among them, two patients were dropped after the first and second cycles of chemotherapy, respectively, without evaluation. The 40 patients received a total of 287 cycles of R-CVP chemotherapy. The overall response rate was 88% (95% CI, 77–98%) with 24 complete responses (60%). The median duration of response was 28.3 months. After a median follow-up of 38.2 months, the estimated 3-year progression-free survival and overall survival were 59% and 95%, respectively. There were 30/287 cycles (11%) and 5/287 cycles (2%) of grade 3 or 4 neutropenia and febrile neutropenia, respectively. The R-CVP regimen can be an effective and tolerable first-line immunochemotherapy regimen for advanced stage MZL.
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Internal Medicine
Yonsei Authors
사서에게 알리기
RIS (EndNote)
XLS (Excel)


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.